Sera Prognostics Inc. Announces the Appointment of Zhenya Lindgardt to the Board
November 08, 2021 at 04:21 pm EST
Share
Sera Prognostics Inc. announced that Zhenya Lindgardt has joined the Sera Board of Directors. Ms. Lindgardt has served as Chief Executive Officer of The Commons Project Foundation (TCP), Prior to joining TCP, she served as Vice President of Platform and Customer Engagement on the Executive Team at Uber Technologies Inc.
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant motherâs risk of delivering spontaneously before 37 weeksâ gestation.
SERA PROGNOSTICS, INC. 
